pharma · Advanced Solid Tumor · XLO
Xilio Therapeutics
Xilio Therapeutics patent portfolio — 7 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Waltham, USA
- Founded
- 2016
- Employees
- 89
- Programs
- 3
- Drugs
- 0
- Patents
- 7
Xilio Therapeutics patents
7 pharmaceutical patents indexed for Xilio Therapeutics. 0 expire within 24 months.
Xilio Therapeutics has 7 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12384845
Activatable masked anti-CTLA4 binding proteins
granted -
US 12280120
Tumor-specific cleavable linkers
granted -
US 11866476
Masked IL-2-Fc fusion polypeptides
granted -
US 11827686
Masked cytokine polypeptides
granted -
US 11827685
Masked cytokine polypeptides
granted -
US 11718655
Masked interleukin-12 polypeptides
granted -
US 11053294
Masked cytokine polypeptides
granted
Frequently asked questions
How many patents does Xilio Therapeutics have?
7 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Xilio Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.